BRPI0410423A - processo de imunogenicidade melhorada para vacinação meningocócica - Google Patents

processo de imunogenicidade melhorada para vacinação meningocócica

Info

Publication number
BRPI0410423A
BRPI0410423A BRPI0410423-4A BRPI0410423A BRPI0410423A BR PI0410423 A BRPI0410423 A BR PI0410423A BR PI0410423 A BRPI0410423 A BR PI0410423A BR PI0410423 A BRPI0410423 A BR PI0410423A
Authority
BR
Brazil
Prior art keywords
improved immunogenicity
immunogenicity
vaccination
meningococcal vaccination
improved
Prior art date
Application number
BRPI0410423-4A
Other languages
English (en)
Inventor
Robert P Ryall
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of BRPI0410423A publication Critical patent/BRPI0410423A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine

Abstract

"PROCESSO DE IMUNOGENICIDADE MELHORADA PARA VACINAçãO MENINGOCóCICA". A presente invenção refere-se a um processo de imunogenicidade melhorada contra sorogrupos A, C, W-1 35 e Y de Neisseria meningitidis.
BRPI0410423-4A 2003-05-07 2004-05-07 processo de imunogenicidade melhorada para vacinação meningocócica BRPI0410423A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46858303P 2003-05-07 2003-05-07
PCT/US2004/014337 WO2005004909A2 (en) 2003-05-07 2004-05-07 Method of enhanced immunogenicity to meningococcal vaccination

Publications (1)

Publication Number Publication Date
BRPI0410423A true BRPI0410423A (pt) 2006-06-06

Family

ID=34061894

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410423-4A BRPI0410423A (pt) 2003-05-07 2004-05-07 processo de imunogenicidade melhorada para vacinação meningocócica

Country Status (8)

Country Link
US (1) US20050002948A1 (pt)
EP (2) EP2301571A1 (pt)
JP (2) JP2007516219A (pt)
CN (1) CN1819843A (pt)
AU (2) AU2004255526A1 (pt)
BR (1) BRPI0410423A (pt)
CA (1) CA2524853A1 (pt)
WO (1) WO2005004909A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2228454T3 (es) * 1999-02-26 2005-04-16 Chiron S.R.L. Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
GB0406013D0 (en) * 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
WO2005105140A2 (en) * 2004-04-30 2005-11-10 Chiron Srl Meningococcal conjugate vaccination
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US20060088554A1 (en) * 2004-08-30 2006-04-27 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
JP5135220B2 (ja) 2005-09-01 2013-02-06 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 血清群c髄膜炎菌を含む複数ワクチン接種
MX2007007790A (es) * 2005-12-22 2009-06-05 Sanofi Pasteur Inc Conjugados y vacuna de proteina con polisacarido derivado meningococcal multivalente.
JP2009520771A (ja) * 2005-12-23 2009-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム コンジュゲートワクチン
KR20130135399A (ko) 2006-03-17 2013-12-10 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
WO2007116409A2 (en) 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
US7491517B2 (en) 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
US8394391B2 (en) * 2007-08-31 2013-03-12 University Of Utah Research Foundation Drug delivery vehicle that mimics viral properties
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
WO2010139047A1 (en) * 2009-06-01 2010-12-09 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Reagents and methods for detecting influenza virus proteins
EP2550289A4 (en) * 2010-03-12 2013-11-27 Childrens Medical Center NEW IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOF
MX347471B (es) * 2010-05-28 2017-04-24 Zoetis Belgium S A Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
CN102462839B (zh) * 2010-11-12 2016-03-30 北京生物制品研究所 多糖结合疫苗及其制备方法
RU2632651C2 (ru) 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
US10428955B2 (en) * 2012-06-25 2019-10-01 Hamilton Sundstrand Corporation Contamination resistant butterfly valve
CN103100081A (zh) * 2012-12-26 2013-05-15 天津康希诺生物技术有限公司 一种多价联合疫苗
EP2953638B1 (en) 2013-02-07 2023-07-05 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
CN107674118A (zh) * 2016-08-02 2018-02-09 中国食品药品检定研究院 重组蛋白PspA1、PspA2和PspA3以及包含其的多糖结合疫苗
CN106167519A (zh) * 2016-08-10 2016-11-30 成都生物制品研究所有限责任公司 一种破伤风类毒素的制备方法
CA3061709A1 (en) 2017-03-28 2018-10-04 The Children's Medical Center Corporation A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
EP3641828B1 (en) 2017-06-23 2023-11-22 Affinivax, Inc. Immunogenic compositions
PE20211112A1 (es) 2018-09-12 2021-06-22 Affinivax Inc Vacunas neumococicas multivalentes
CN109402035A (zh) * 2018-11-06 2019-03-01 华中农业大学 一种肠外致病性大肠杆菌重组菌株及其应用
CN111024946A (zh) * 2019-11-19 2020-04-17 江苏美克医学技术有限公司 阴道毛滴虫荧光免疫层析测定试剂盒及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5422427A (en) 1991-09-17 1995-06-06 The United States Of America As Represented By The United States Department Of Health And Human Services Pneumococcal fimbrial protein A
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
DK1946769T3 (da) 2000-06-29 2012-07-16 Smithkline Beecham Biolog Multivalent vaccinesammensætning med nedsat dosis af Haemophilus influenzae type B
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
US8722062B2 (en) * 2001-01-23 2014-05-13 Sanofi Pasteur, Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine

Also Published As

Publication number Publication date
JP2011068676A (ja) 2011-04-07
AU2010257354A1 (en) 2011-01-20
AU2004255526A1 (en) 2005-01-20
US20050002948A1 (en) 2005-01-06
WO2005004909A3 (en) 2005-06-02
CN1819843A (zh) 2006-08-16
EP1626737A2 (en) 2006-02-22
EP2301571A1 (en) 2011-03-30
CA2524853A1 (en) 2005-01-20
JP2007516219A (ja) 2007-06-21
WO2005004909A2 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
BRPI0410423A (pt) processo de imunogenicidade melhorada para vacinação meningocócica
BR0112928A (pt) Vacinas para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
DK1741442T3 (da) Neisseria meningitidis-kombinationavacciner
HK1087946A1 (en) Liquid vaccines for multiple meningococcal serogroups
CR10123A (es) Vacuna.
RU2006140958A (ru) Иммунизация против менингококков серогруппы y с помощью белков
PT1777236T (pt) Sacáridos modificados possuindo estabilidade melhorada em água para utilização como um medicamento
MA30065B1 (fr) Vaccin
AP2002002681A0 (en) Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup a and proces for the production thereof
NZ598367A (en) Multiple vaccination including serogroup C meningococcus
EP2433647A3 (en) GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
ATE552844T1 (de) Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
BR0015958A (pt) Composições que compreendem antìgenos de neisseria meningitidis de sorogrupos b e c
ZA200306176B (en) Multivalent meningococcal polysaccharide-protein conjugate vaccine.
EP1379272A4 (en) MOLECULAR MIMETICS OF MENINGOKOKEN B EPITOPES THAT MAKE THE FORMATION OF FUNCTIONALLY EFFECTIVE ANTIBODIES
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
WO2003047619A3 (en) Adjuvanted antigenic meningococcal compositions
BRPI0411815A (pt) vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas
WO2010027499A3 (en) Methods, compositions and vaccines relating to neisseria meningitidis antibodies
NO20026049D0 (no) Protein-basert vaksine mot meningokokk serogruppe W-135 sykdom

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.